
SMS Pharmaceuticals Ltd is Rated Sell
2026-08-09 10:10:17SMS Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 06 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 09 August 2026, providing investors with the most recent and relevant data to assess the company’s outlook.
Read full news articleAre SMS Pharmaceuticals Ltd latest results good or bad?
2026-08-02 19:12:30The latest financial results for SMS Pharmaceuticals Ltd for the quarter ended June 2026 present a mixed operational picture. The company reported a consolidated net profit of ₹20.91 crores, reflecting a year-on-year growth of 2.05%, which indicates some resilience compared to the same period last year. However, this figure represents a significant quarter-on-quarter decline of 36.07% from ₹32.71 crores in March 2026, highlighting volatility in profitability. In terms of revenue, SMS Pharmaceuticals achieved net sales of ₹206.96 crores, which marks a year-on-year increase of 5.56% from ₹196.05 crores in June 2025. Conversely, the sequential comparison shows a decline of 13.02% from ₹237.95 crores in the previous quarter, suggesting challenges in maintaining consistent sales momentum. Despite the pressures on sales and profit, the company demonstrated effective cost management, as evidenced by an operating...
Read full news article
SMS Pharmaceuticals Q1 FY27: Margin Resilience Amid Revenue Headwinds
2026-08-01 13:17:37SMS Pharmaceuticals Ltd., a Hyderabad-based active pharmaceutical ingredients (API) manufacturer, reported a mixed performance for Q1 FY27 (June 2026 quarter), with consolidated net profit rising 2.05% year-on-year to ₹20.91 crores despite a 13.02% sequential revenue decline. The ₹3,526 crore market capitalisation company demonstrated margin resilience even as topline pressures emerged, raising questions about sustainability of growth momentum in an increasingly competitive pharmaceutical landscape.
Read full news article
SMS Pharmaceuticals Ltd Valuation Shifts Amidst Market Volatility
2026-07-31 08:00:24SMS Pharmaceuticals Ltd has recently undergone a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating. This change, coupled with a downgrade in its Mojo Grade from Hold to Sell, reflects evolving market perceptions and valuation dynamics within the Pharmaceuticals & Biotechnology sector. This article examines the implications of these valuation changes, comparing SMS Pharma’s metrics against its peers and historical benchmarks to assess its price attractiveness and investment appeal.
Read full news articleWhen is the next results date for SMS Pharmaceuticals Ltd?
2026-07-30 23:16:50The next results date for SMS Pharmaceuticals Ltd is scheduled for August 1, 2026....
Read full news article
SMS Pharmaceuticals Ltd is Rated Sell
2026-07-29 10:11:32SMS Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 06 Jul 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 29 July 2026, providing investors with the latest perspective on the company’s position.
Read full news article
SMS Pharmaceuticals Ltd is Rated Sell
2026-07-18 10:10:51SMS Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
MarketsMOJO Downgrades SMS Pharmaceuticals Ltd to Sell Amid Mixed Technicals and Valuation Concerns
2026-07-07 08:13:30SMS Pharmaceuticals Ltd has seen its investment rating downgraded from Hold to Sell, reflecting a complex interplay of technical indicators, valuation metrics, financial trends, and quality assessments. Despite impressive market-beating returns over recent years, the company faces challenges that have prompted a reassessment of its investment appeal.
Read full news article
SMS Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
2026-07-07 08:03:10SMS Pharmaceuticals Ltd has experienced a nuanced shift in its technical momentum, with key indicators signalling a transition from a bullish to a mildly bullish trend. Despite a slight dip in daily price, the stock’s medium and long-term technicals reveal a complex interplay of bullish and bearish signals, prompting a reassessment of its near-term outlook within the Pharmaceuticals & Biotechnology sector.
Read full news articleIntimation On Tax Deduction At Source On Dividend
06-Aug-2026 | Source : BSEPlease find the enclosure
Announcement under Regulation 30 (LODR)-Press Release / Media Release
01-Aug-2026 | Source : BSEPress Release on Financial Results
Announcement under Regulation 30 (LODR)-Newspaper Publication
01-Aug-2026 | Source : BSECopy of Newspaper Publication
Corporate Actions
No Upcoming Board Meetings
SMS Pharmaceuticals Ltd has declared 40% dividend, ex-date: 22 Sep 25
SMS Pharmaceuticals Ltd has announced 1:10 stock split, ex-date: 17 Dec 15
No Bonus history available
No Rights history available






